Syndax Q1 Revenue Soars 224% to $64.9M, Revuforj Hits $48.9M
Syndax posted $64.9 million revenue in first quarter 2026, up 224% year-over-year, driven by $48.9 million Revuforj net sales and $15.9 million collaboration revenue from Niktimvo. The company forecasts new Revuforj real-world and post-HSCT maintenance data in 2Q26 and Phase 2 axatilimab topline results in 4Q26, supporting long-term growth.
1. Q1 Financial Performance
Syndax reported $64.9 million total revenue in 1Q26, up 224% year-over-year, driven by $48.9 million Revuforj net sales (144% growth y/y, 11% q/q) and $15.9 million collaboration revenue from Niktimvo.
2. Product Revenue Drivers
Revuforj prescriptions rose approximately 160% year-over-year in relapsed or refractory NPM1m AML, solidifying leadership in menin inhibition while Niktimvo generated $55.1 million net revenue, producing $15.9 million collaboration revenue.
3. Upcoming Data Catalysts
The company expects new real-world and post-HSCT maintenance data for Revuforj in 2Q26 and topline Phase 2 axatilimab results in 4Q26 for IPF and frontline chronic GVHD, underpinning further commercial momentum.
4. Clinical Pipeline and Trials
Ongoing pivotal trials include EVOLVE-2 and REVEAL-ND Phase 3 studies in frontline AML, SAVE combination trials, the BEAT AML master trial, and post-transplant maintenance evaluations for revumenib across acute leukemia indications.